| Company Name: |
Sigma-Aldrich |
| Tel: |
021-61415566 800-8193336 |
| Email: |
orderCN@merckgroup.com |
| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
BRACO 19 manufacturers
- Braco-19
-
- $48.00
-
2026-04-23
- CAS:351351-75-2
- Purity: 97.01%
- Supply Ability: 10g
|
| | BRACO 19 Basic information |
| Product Name: | BRACO 19 | | Synonyms: | BRACO 19;BRACO 19 1-Pyrrolidinepropaneamide;1-Pyrrolidinepropanamide, N,N'-[9-[[4-(dimethylamino)phenyl]amino]-3,6-acridinediyl]bis-;N,N'-(9-((4-(Dimethylamino)phenyl)amino)acridine-3,6-diyl)bis(3-(pyrrolidin-1-yl)propanamide);N,N'-(9-((4-(Dimethylamino)phenyl)amino)acridine-3,6-diyl)bis(3-(pyrrolidin-1-yl)propanamide) | | CAS: | 351351-75-2 | | MF: | C35H43N7O2 | | MW: | 593.76 | | EINECS: | | | Product Categories: | | | Mol File: | 351351-75-2.mol |  |
| | BRACO 19 Chemical Properties |
| Melting point | >320 °C | | Boiling point | 854.9±65.0 °C(Predicted) | | density | 1.274±0.06 g/cm3(Predicted) | | pka | 12.93±0.43(Predicted) | | form | Solid | | color | Brown to orange |
| | BRACO 19 Usage And Synthesis |
| Uses | Braco-19 is a potenttelomerase/telomereinhibitor, preventing the capping and catalytic action of telomerase. Braco-19 acts as G-quadruplex (GQ) binding ligand, stabilizing G-quadruplexes formation at the 3V telomeric DNA overhang and produce rapid senescence or selective cell death. Braco-19 is also a HAdV virusreplication inhibitor[1][2]. | | Definition | ChEBI: N,N'-(9-{[4-(dimethylamino)phenyl]amino}acridine-3,6-diyl)bis(3-pyrrolidin-1-ylpropanamide) is a member of acridines and a N-alkylpyrrolidine. | | in vivo | BRACO-19 (oral administration or intraperitoneal injection; 2 or 5 mg/kg; 3 weeks) oral dosing regimen are always inactive and the animals have to be sacrificed due to high tumor burden before overall termination of the study, Chronic, i.p. BRACO-19 administration, qdx5 is efficient in inhibiting tumor growth in earlystage xenografts but not advanced-stage xenografts[1]. BRACO-19 (intraperitoneal injection; 2 mg/kg; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments) inhibits tumor growth significantly and under these conditions, marked single-agent antitumor activity is observed, with some animals in the group showing complete regressions (5 of 12 tumors)[1]. | Animal Model: | Established UXF1138LX Xenografts in nude mice[1] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection; 3 weeks; starting 6 days after transplantation of UXF1138LX fragments | | Result: | Showed partial tumor regressions with an optimal T/C on day 28 of 4.1%, equal to 95.9% inhibition of tumor growth compared with control. |
| | References | [1] Angelika M Burger, et al. The G-quadruplex-interactive Molecule BRACO-19 Inhibits Tumor Growth, Consistent With Telomere Targeting and Interference With Telomerase Function. Cancer Res. 2005 Feb 15;65(4):1489-96. DOI:10.1158/0008-5472.CAN-04-2910
[2] Prativa Majee, et al. Genome-wide Analysis Reveals a Regulatory Role for G-quadruplexes During Adenovirus Multiplication. Virus Res. .2020 Jul DOI:10.1016/j.virusres.2020.197960 |
| | BRACO 19 Preparation Products And Raw materials |
|